AAPS PharmSciTech

, Volume 14, Issue 1, pp 151–159 | Cite as

Low-Viscosity Hydroxypropylcellulose (HPC) Grades SL and SSL: Versatile Pharmaceutical Polymers for Dissolution Enhancement, Controlled Release, and Pharmaceutical Processing

  • Ashish Sarode
  • Peng Wang
  • Catherine Cote
  • David R. Worthen
Research Article

Abstract

Hydroxypropylcellulose (HPC)-SL and -SSL, low-viscosity hydroxypropylcellulose polymers, are versatile pharmaceutical excipients. The utility of HPC polymers was assessed for both dissolution enhancement and sustained release of pharmaceutical drugs using various processing techniques. The BCS class II drugs carbamazepine (CBZ), hydrochlorthiazide, and phenytoin (PHT) were hot melt mixed (HMM) with various polymers. PHT formulations produced by solvent evaporation (SE) and ball milling (BM) were prepared using HPC-SSL. HMM formulations of BCS class I chlorpheniramine maleate (CPM) were prepared using HPC-SL and -SSL. These solid dispersions (SDs) manufactured using different processes were evaluated for amorphous transformation and dissolution characteristics. Drug degradation because of HMM processing was also assessed. Amorphous conversion using HMM could be achieved only for relatively low-melting CBZ and CPM. SE and BM did not produce amorphous SDs of PHT using HPC-SSL. Chemical stability of all the drugs was maintained using HPC during the HMM process. Dissolution enhancement was observed in HPC-based HMMs and compared well to other polymers. The dissolution enhancement of PHT was in the order of SE > BM > HMM > physical mixtures, as compared to the pure drug, perhaps due to more intimate mixing that occurred during SE and BM than in HMM. Dissolution of CPM could be significantly sustained in simulated gastric and intestinal fluids using HPC polymers. These studies revealed that low-viscosity HPC-SL and -SSL can be employed to produce chemically stable SDs of poorly as well as highly water-soluble drugs using various pharmaceutical processes in order to control drug dissolution.

KEY WORDS

controlled release formulations hydroxypropylcellulose melt extrusion solid dispersion 

References

  1. 1.
    Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Desai D, Kothari S, Chen W, Wang J, Huang M, Sharma L. Fatty acid and water-soluble polymer-based controlled release drug delivery system. J Pharm Sci. 2011;100(5):1900–12.PubMedCrossRefGoogle Scholar
  4. 4.
    Timpe C, Forschung L. Strategies for formulation development of poorly water-soluble drug candidates—a recent perspective. Am Pharm Rev. 2007;10(2):104–9.Google Scholar
  5. 5.
    Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23–24):1068–75.PubMedCrossRefGoogle Scholar
  6. 6.
    Repka MA, Majumdar S, Kumar-Battu S, Srirangam R, Upadhye SB. Applications of hot-melt extrusion for drug delivery. Expert Opin Drug Deliv. 2008;5(12):1357–76.PubMedCrossRefGoogle Scholar
  7. 7.
    Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F, et al. Pharmaceutical applications of hot-melt extrusion: part II. Drug Dev Ind Pharm. 2007;33(10):1043–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Bruce LD, Shah NH, Malick AW, Infeld MH, McGinity JW. Properties of hot-melt extruded tablet formulations for the colonic delivery of 5-aminosalicylic acid. Eur J Pharm Biopharm. 2005;59(1):85–97.PubMedCrossRefGoogle Scholar
  9. 9.
    Fukuda M, Peppas NA, McGinity JW. Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum. Int J Pharm. 2006;310(1–2):90–100.PubMedCrossRefGoogle Scholar
  10. 10.
    Verhoeven E, Vervaet C, Remon JP. Xanthan gum to tailor drug release of sustained-release ethylcellulose mini-matrices prepared via hot-melt extrusion: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2006;63(3):320–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Zelko R, Kiss D. Physical ageing of amorphous polymeric excipients I. physicochemical principles. Acta Pharm Hung. 2005;75(4):213–22.PubMedGoogle Scholar
  12. 12.
    Zelko R, Kiss D. Physical ageing of amorphous polymeric excipients III. The possible consequences of ageing. Acta Pharm Hung. 2006;76(2):105–13.PubMedGoogle Scholar
  13. 13.
    DiNunzio JC, Brough C, Miller DA, Williams 3rd RO, McGinity JW. Applications of KinetiSol dispersing for the production of plasticizer free amorphous solid dispersions. Eur J Pharm Sci. 2010;40(3):179–87.PubMedCrossRefGoogle Scholar
  14. 14.
    Stukalin EB, Douglas JF, Freed KF. Plasticization and antiplasticization of polymer melts diluted by low molar mass species. J Chem Phys. 2010;132(8):084504.PubMedCrossRefGoogle Scholar
  15. 15.
    Ghosh I, Snyder J, Vippagunta R, Alvine M, Vakil R, Tong WQ, et al. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder. Int J Pharm. 2011;419(1–2):12–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Picker-Freyer KM, Durig T. Physical mechanical and tablet formation properties of hydroxypropylcellulose: in pure form and in mixtures. AAPS PharmSciTech. 2007;8(4):E92.PubMedCrossRefGoogle Scholar
  17. 17.
    Dinunzio JC, Brough C, Hughey JR, Miller DA, Williams 3rd RO, McGinity JW. Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and kinetisol dispersing. Eur J Pharm Biopharm. 2010;74(2):340–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Zhou J, Zhang L, Deng Q, Wu X. Synthesis and characterization of cellulose derivatives prepared in NaOH/urea aqueous solutions. J Polym Sci A Polym Chem. 2004;14(23):5911–20.CrossRefGoogle Scholar
  19. 19.
    Ambike AA, Mahadik KR, Paradkar A. Stability study of amorphous valdecoxib. Int J Pharm. 2004;282(1–2):151–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Seurin MJ, ten Bosch A, Sixou P. Phase studies of a liquid crystalline polymer: hydroxypropyl cellulose. Polym Bull. 1983;9:450–6.CrossRefGoogle Scholar
  21. 21.
    Suto S, Ohshiro M, Ito R, Karasawa M. Capillary rheometry of lyotropic liquid crystals of hydroxypropyl cellulose. Polymer. 1987;28(1):23–32.CrossRefGoogle Scholar
  22. 22.
    Vshivkov SA, Adamova L, Rusinova EV, Safronov AP, Dreval’ VE, Galyas AG. Thermodynamics of liquid-crystalline solutions of hydroxypropyl cellulose in water and ethanol. Polym Sci Ser A. 2007;49(5):578–83.CrossRefGoogle Scholar
  23. 23.
    Kawashima Y, Takeuchi H, Hino T, Niwa T, Lin TL, Sekigawa F, et al. Low-substituted hydroxypropylcellulose as a sustained-drug release matrix base or disintegrant depending on its particle size and loading in formulation. Pharm Res. 1993;10(3):351–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Camara MS, Mastandrea C, Goicoechea HC. Chemometrics-assisted simple UV-spectroscopic determination of carbamazepine in human serum and comparison with reference methods. J Biochem Biophys Methods. 2005;64(3):153–66.PubMedCrossRefGoogle Scholar
  25. 25.
    Hemke AT, Bhure MV, Chouhan KS, Gupta KR, Wadodkar SG. UV spectrophotometric determination of hydrochlorothiazide and olmesartan medoxomil in pharmaceutical formulation. E-J Chem. 2010;7(4):1156–61.CrossRefGoogle Scholar
  26. 26.
    Leung CP, Law CK. Determination of chlorpheniramine maleate in tablets by second-derivative absorption spectrophotometry. Analyst. 1989;114(2):241–2.PubMedCrossRefGoogle Scholar
  27. 27.
    Rezaei Z, Hemmateenejad B, Khabnadideh S, Gorgin M. Simultaneous spectrophotometric determination of carbamazepine and phenytoin in serum by PLS regression and comparison with HPLC. Talanta. 2005;65(1):21–8.PubMedGoogle Scholar
  28. 28.
    Srinivasa Rao K, Belorkar N. Development and validation of a specific stability indicating liquid chromatographic method for carbamazepine in bulk and pharmaceutical dosage forms. J Adv Pharm Res. 2010;1:36–47.Google Scholar
  29. 29.
    Tagliari MP, Stulzer H, Murakami FS, Kuminek G, Valente B, Oliveira PR, Silva MA. Development and validation of a stability-indicating LC method to quantify hydrochlorothiazide in oral suspension for pediatric use. Chromatographia. 2008;67(7–8):647–52.CrossRefGoogle Scholar
  30. 30.
    Rumondor AC, Taylor LS. Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. Mol Pharm. 2009;7(2):477–90.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2012

Authors and Affiliations

  • Ashish Sarode
    • 1
    • 2
  • Peng Wang
    • 1
    • 2
  • Catherine Cote
    • 3
  • David R. Worthen
    • 1
    • 2
  1. 1.Department of Biomedical and Pharmaceutical Sciences, College of PharmacyUniversity of Rhode IslandKingstonUSA
  2. 2.Department of Chemical Engineering, College of EngineeringUniversity of Rhode IslandKingstonUSA
  3. 3.Nisso America, Inc.New YorkUSA

Personalised recommendations